FDA-approved medication
Zepbound (tirzepatide)
Key facts
Last reviewed: 2026-11-04- •FDA label says "ZEPBOUND ® (tirzepatide) Injection, for subcutaneous use".
- •FDA label says "ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity."
- •FDA label says "The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks. Increase the dosage in 2.5 mg increments after at least 4 weeks until recommended maintenance dosage is achieved."
- •FDA label says "Weight Reduction and Long-Term Maintenance: 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly. ( 2.2 ) Obstructive Sleep Apnea: 10 mg or 15 mg injected subcutaneously once weekly. ( 2.2 ) Maximum Recommended Dosage: 15 mg injected subcutaneously once weekly."
FDA-approved to reduce excess body weight and maintain weight reduction long term. Read the dose schedule and safety information, and check the official prescribing information. Confirm costs and coverage with your pharmacy, insurer, or the manufacturer.
tirzepatide · single-dose pen or single-dose vial; multi-dose vial or single-patient-use KwikPen · once weekly, subcutaneous
- Active ingredient
- tirzepatide
- Dosage form (label)
- Injection: single-dose pen or single-dose vial; multi-dose vial or single-patient-use KwikPen
- Schedule (label)
- Once weekly, subcutaneous
- Strengths (label)
- 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
- Manufacturer
- Eli Lilly and Company; marketed by Lilly USA, LLC (per label)
Brand names are trademarks of their respective owners; this site is not affiliated with them.

FDA label
Zepbound dose steps (FDA label)
- 2.5 mgWeeks 1–4Starting dose
- 5 mg≥ 4 weeksDose step
- 7.5 mg≥ 4 weeksDose step
- 10 mg≥ 4 weeksDose step
- 12.5 mg≥ 4 weeksDose step
- 15 mgLabel maximumMaximum dose
FDA label answers
Common questions about Zepbound
All answers are taken directly from the official FDA prescribing information (FDA Prescribing Information (DailyMed setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, SPL version 40, revised 08/2026)).
Who is Zepbound approved for?
FDA label says "ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity."
How often is Zepbound taken?
FDA label says "The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks. Increase the dosage in 2.5 mg increments after at least 4 weeks until recommended maintenance dosage is achieved."
What are the most common side effects listed on the label for Zepbound?
FDA label says "The most common adverse reactions, reported in ≥5% of patients treated with ZEPBOUND are: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease."
Is there a boxed warning on the Zepbound label?
Yes. FDA label says "WARNING: RISK OF THYROID C-CELL TUMORS" — "In rats, tirzepatide causes thyroid C-cell tumors."
What are the recommended maintenance dosages for Zepbound?
FDA label says "Weight Reduction and Long-Term Maintenance: 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly. ( 2.2 ) Obstructive Sleep Apnea: 10 mg or 15 mg injected subcutaneously once weekly. ( 2.2 ) Maximum Recommended Dosage: 15 mg injected subcutaneously once weekly."
Next Steps: Evaluating Zepbound for Your Care Plan
Transition from drug facts to clinical action. Estimate potential out-of-pocket expenses, generate consultation questions, and verify eligibility.
Out-of-Pocket Expense Modeling
Estimate what you might pay each month based on manufacturer assistance terms and employer benefit design.
Consultation & Lab Checklist
Arrive at your appointment prepared with essential baseline bloodwork requirements and contraindication screens.
BMI Qualification & Directory
Verify your body mass index against official FDA prescribing label requirements and locate qualified clinicians.
Editorial & Regulatory Standard: TrimSoMo is an independent, non-commercial healthcare information platform. Estimated out-of-pocket costs and savings card parameters reflect publicly published 2026 manufacturer program guidelines and do not guarantee individual insurance coverage or pharmacy dispensing prices. Prescriptions require clinical evaluation by a licensed physician.
Before Starting Zepbound
Gradual Dose Titration
Per the FDA label, doses start low and increase over several months to help reduce gastrointestinal side effects. Your clinician sets your schedule. Review post-marketing data in our GLP-1 side effects from FDA labels → FAERS reports do not prove cause.
Lifestyle & Nutrition Support
In clinical studies, medication was used together with a reduced-calorie diet and increased physical activity.
Long-Term Plan
Talk with your clinician before changing or stopping treatment.
In-Depth Clinical Guides
Explore our clinical reviews, FDA label comparisons, and insurance navigation guides for Zepbound.
Dose Escalation Schedule
Tirzepatide titration from 2.5 mg starter to 5, 10, or 15 mg maintenance dosing.
Comparing GLP-1 Medications
Dual GIP/GLP-1 mechanisms vs single GLP-1 agonists, and clinician discussion points.
BMI Requirements & Indications
FDA label criteria for chronic weight management and obstructive sleep apnea.
Prior Authorization & Appeals Guide
Documenting comorbidities and submitting prior authorizations for Zepbound.
Exploring non-injectable options?
Some oral GLP-1 medicines are FDA-approved and others are still in development. The list shows each medicine's status and source.